医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Trio-Tech Temporarily Closes Facility to Comply with Tianjin City COVID-19 Safety and Restriction Measures

2022年01月19日 PM10:30
このエントリーをはてなブックマークに追加


 

VAN NUYS, Calif.

Trio-Tech International (NYSE MKT: TRT) today announced that it is in full compliance with the Tianjin City Government’s Business Closure lockdown.

S.W. Yong, Trio-Tech’s CEO, said, “In response to a local COVID-19 outbreak and in compliance with China’s ZERO-Covid policy, the Tianjin city government imposed lockdown measures for mandatory testing of its Tianjin city’s residents which affected Trio-Tech’s Tianjin China Operations and required us to close our facility’s production line.”

“Trio-Tech is seriously concerned with the threat posed by spread of COVID-19 and has ensured that stringent health and safety measures are in place throughout our facilities. It is the utmost concern of Trio-Tech to defend and support the health and safety of all our employees, customers, suppliers and the Tianjin community as a whole. We will actively address this closure and proactively work with our customers and suppliers to manage and minimize the impact of this temporary closure. We plan to resume operations once the city government allows for the reopening of businesses,” added Mr. Yong.

About Trio‑Tech

Established in 1958, Trio-Tech International is located in Van Nuys, California, with its Principal Executive Office and regional headquarter in Singapore. Trio-Tech International is a diversified business group with interests in semiconductor testing services, manufacturing and distribution of semiconductor testing equipment, and real estate. Our subsidiary locations include Tianjin, Suzhou, Chongqing in China, as well as Kuala Lumpur Malaysia and Bangkok Thailand. Further information about Trio-Tech’s semiconductor products and services can be obtained from the Company’s Web site at www.triotech.com and www.universalfareast.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005466/en/

CONTACT

Company Contact:

A. Charles Wilson

Chairman

(818) 787-7000

Investor Contact:

Berkman Associates

(310) 927-3108

robert.jacobs@jacobscon.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • PCI Pharma Services宣布在新英格兰投资1亿美元进行重大生产扩张,为客户提供全球产能
  • PCIファーマ・サービシズがニューイングランド施設に1億ドルを投じ、大規模な生産拡張により顧客に世界的能力を提供すると発表
  • Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
  • Trinity Life Sciences Announces the Opening of State-of-the-art Office in India
  • PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas